Albuminuria-Lowering Effect of Adding Semaglutide on Top of Empagliflozin in Individuals with Type 2 Diabetes: A Randomized and Placebo-Controlled Study
Diabetes Obes Metab. 2023; online ahead of print DOI: 10.1111/dom.15287
The proposed different mechanisms of SGLT2i and GLP-1RAs indicate that combination therapy may have additive or synergistic effects on the kidneys. This placebo-controlled, double-blind, parallel-group study investigated the effect on albuminuria of adding semaglutide to ongoing treatment with empagliflozin compared with empagliflozin alone in 60 individuals with T2D and albuminuria.
The addition of semaglutide to empagliflozin did not significantly affect the primary endpoint of change in UACR from baseline to week 26 compared with placebo. Furthermore, semaglutide added to empagliflozin did not change measured GFR, 24-h SBP, body weight or plasma renin levels at week 26, but did improve glycaemic control and plasma aldosterone levels compared with placebo.
Keywords:
